Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

Launched by WEST CHINA HOSPITAL · Apr 28, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how a combination of immunotherapy and chemotherapy, given before surgery, can affect the treatment outcomes for patients with locally advanced non-small cell lung cancer (NSCLC) at stage IIIA or IIIB. The goal is to understand if this approach can improve both the short-term results during and after surgery, as well as the long-term chances of recovery.

To be eligible for this trial, participants should be at least 18 years old and have been diagnosed with primary lung cancer through specific tests. They must also have a good performance status, meaning they are able to carry out daily activities without much trouble. Additionally, participants should not have certain genetic mutations related to lung cancer, and they need to agree to receive the new treatment before surgery. This trial is currently not recruiting patients, but it aims to provide valuable insights into how this treatment combination can help improve care for lung cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed as primary lung cancer through cytology or histological examination;
• • ECOG score of 0 or 1; ③ 18 years old or above;
• • Received imaging examination, with a preliminary clinical staging of stage III;
• • Received genetic testing and tested negative for EGFR mutations, ALK or ROS-1 fusion; ⑥ Accepting preoperative neoadjuvant immunotherapy combined with chemotherapy; ⑦ Receive surgical treatment after completion of neoadjuvant therapy; ⑧ The postoperative specimens were sent to the pathology department of our hospital for pathological testing, and a complete pathological report is available.
• Exclusion Criteria:
• • Patients with combined small cell lung cancer; ② Patients with severe liver/kidney dysfunction, cardiovascular disease, or systemic immune disorders;
• • Accept other neoadjuvant treatments; ④ Patients participating in any clinical trial.